Holen Sie sich die Stockscreener-App
213.67
0.00%
-0.01
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
GSA Capital Partners LLP Makes New $2.31 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
AXSM Stock Advances On CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030 - Stocktwits
AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism? - Stocktwits
AXSM Stock In Spotlight Ahead Of Key FDA Verdict On Alzheimer’s Drug This Week - Stocktwits
Axsome Therapeutics, Inc. (AXSM) Latest Stock News & Headlines - Yahoo Finance
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $316 - moomoo.com
Handelsbanken Fonder AB Has $10.38 Million Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
AXSOME THERAPEUTICS Q2 2026 Earnings Preview: Recent $AXSM Insider Trading, Hedge Fund Activity, and More - moomoo.com
AXSM|Axsome Therapeutics Inc|Price:213.630|Chg%:-1.030 - TradingKey
If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Axsome Therapeutics (NASDAQ:AXSM) Faces A Crucial Test - Kalkine Media
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - simplywall.st
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
AXSOME THERAPEUTICS, INC. : MIZUHO RAISES TARGET PRICE TO $316 FROM $306 - webull.com
UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating - moomoo.com
Mizuho raises Axsome Therapeutics stock price target on Auvelity By Investing.com - Investing.com South Africa
Mizuho raises Axsome Therapeutics stock price target on Auvelity - Investing.com
Mizuho Adjusts PT on Axsome Therapeutics to $316 From $306, Keeps Outperform Rating - marketscreener.com
Quantinno Capital Management LP Acquires 5,019 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results - webull.com
Axsome Therapeutics (AXSM) Stock Faces Revenue Momentum And Lingering Losses - sahmcapital.com
AXSOME THERAPEUTICS, INC. : MORGAN STANLEY RAISES TARGET PRICE TO $251 FROM $242 - webull.com
Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues - TradingView
Axsome Therapeutics (AXSM) Shares Just Climbed, So What Is Driving Attention Now? - Yahoo Finance
RBC cuts Axsome Therapeutics stock price target on model updates By Investing.com - Investing.com Australia
Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition (AXSM) - Seeking Alpha
Axsome's Auvelity Strength Expected to Drive H2 Revenue Growth, RBC Says - marketscreener.com
Axsome Therapeutics Is Maintained at Outperform by RBC Capital - moomoo.com
Wells Fargo raises Axsome Therapeutics price target to $256 By Investing.com - Investing.com Australia
RBC cuts Axsome Therapeutics stock price target on model updates - Investing.com
Needham raises Axsome Therapeutics stock price target on drug growth By Investing.com - Investing.com South Africa
AXSM Maintained by Wells Fargo -- Price Target Raised to $256 - GuruFocus
Guggenheim raises Axsome Therapeutics stock price target on sales beat By Investing.com - Investing.com Nigeria
Needham raises Axsome Therapeutics stock price target on drug growth - Investing.com
Morgan Stanley Adjusts Axsome Therapeutics PT to $251 From $242, Keeps Equalweight Rating - marketscreener.com
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $268.00 - MarketBeat
Guggenheim raises Axsome Therapeutics stock price target on sales beat - Investing.com
Does Axsome Therapeutics (AXSM) Look Fairly Valued At This Price? - Yahoo Finance
RBC Adjusts PT on Axsome Therapeutics to $297 From $304, Maintains Outperform Rating - marketscreener.com
Faster Revenue Growth With Wider Losses Might Change The Case For Investing In Axsome (AXSM) - sahmcapital.com
Axsome Therapeutics Inc earnings missed by $0.14, revenue fell short of estimates By Investing.com - Investing.com Australia
Axsome Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:AXSM) 2026-08-11 - Seeking Alpha
AXSOME THERAPEUTICS Q2 OPERATING INCOME USD -49.646 MILLION - Moomoo
Axsome Therapeutics, Inc. Stock 12‑Month Price Target Raised to $282.78, Implies 33% Upside - TradingView
Axsome Therapeutics shares rise 2% despite Q2 earnings miss - Investing.com
Axsome Therapeutics 2Q 2026: Revenue $218.4M, EPS $(0.99) — 10-Q Summary - TradingView
Axsome Therapeutics (NASDAQ: AXSM) grows Q2 2026 revenue but remains unprofitable - Stock Titan
Form 8K Axsome Therapeutics Inc For: 10 August By Investing.com - Investing.com Canada
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):